Article
Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal
Rating:
0.0
Views:
112
Likes:
1
Library:
1
Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion. Per the Wall Street Journal, Immunomedics — a biotech known for breast-cancer treatment Trodelvy — was initially a partner of Gilead before takeover talks began. Terms are expected to be announced Monday. Immunomedics, whose valuation hovers $10 billion, […]
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value